Effect of ropivacaine on peripheral neuropathy in streptozocin diabetes-induced rats through TRPV1-CGRP pathway

Abstract

Objective To determine the effect of ropivacaine on peripheral neuropathy in diabetic rats and its possible mechanism.Methods Forty-eight Sprague–Dawley rats were randomly divided into six groups: nondiabetic control group, nondiabetic group A (0.25% ropivacaine), nondiabetic group B (0.75% ropivacaine), diabetic control group (diabetic peripheral neuropathy (DPN) +artificial cerebrospinal fluid), diabetic group A (DPN+0.25% ropivacaine), and diabetic group B (DPN + 0.75% ropivacaine), with eight rats in each group. Within an hour of the last administration, the sciatic motor nerve conduction velocity (MNCV) of each group was measured, and the morphological changes of rat sciatic nerve were observed by HE, Weil’s staining and electron microscopy. The expression of transient receptor potential vanilloid (TRPV1) in the spinal cord dorsal horn of rats was analyzed by immunohistochemistry, and the expression of Calcitonin gene-related peptide (CGRP) protein in the spinal cord was analyzed by Western blot.Results Compared with the nondiabetic control group, elevated blood glucose, decreased weight and reduced average mechanical withdrawal threshold (MWT), additionally, the sciatic nerves showed significantly slowed conduction velocity (both P<0.001) and damaged pathological structure, the expression of TRPV1 and CGRP were decreased (both P<0.001) in the diabetic groups. Compared with the diabetic control group, down-regulation of TRPV1 and CGRP in spinal cord was significant for the diabetic groups A and B treated with 0.25 and 0.75% ropivacaine, the higher concentration of ropivacaine correlated with a greater change.Conclusion Ropivacaine can significantly block sciatic nerve conduction velocity in DPN rats in a concentration-dependent manner, which may be related to the expression of the TRPV1-CGRP pathway.

Modulation of Sensory Nerve Function by Insulin: Possible Relevance to Pain, Inflammation and Axon Growth

“…It has also been demonstrated that expression of these markers were also reduced in peripheral nerves [122]. In addition, it has been shown that ropivacaine, which is a commonly used anesthetic in the treatment of peripheral neuropathy, has a protective effect against the development of diabetic peripheral neuropathy by regulating TRPV1 receptor mediated CGRP release [122]. In agreement with this study, another report has demonstrated that TRPV1 receptor antagonists such as capsazepine prevent hydrogen sulfide-induced hyperalgesia in diabetic rats [123].…”

“…Recent work using immunohistochemistry and western blot analysis has revealed that expression of TRPV1 receptor and CGRP decreased in spinal cord dorsal horn of in rats with streptozotocin (STZ) diabetes. It has also been demonstrated that expression of these markers were also reduced in peripheral nerves [122]. In addition, it has been shown that ropivacaine, which is a commonly used anesthetic in the treatment of peripheral neuropathy, has a protective effect against the development of diabetic peripheral neuropathy by regulating TRPV1 receptor mediated CGRP release [122].…”

Efficacy of topical ropivacaine in children and young adults with hereditary epidermolysis bullosa

“…It reversibly inhibits the nociceptive influx of sodium ions in nerve fibres by blocking propagation of action potentials. It also reduces the activity of the TRPV1 channel 5 . Thus, it may have a role in controlling neuropathic pain.…”

“…It also reduces the activity of the TRPV1 channel. 5 Thus, it may have a role in controlling neuropathic pain. Topical ropivacaine is known to be well tolerated.…”

“…1 Yet despite clindamycin plus rifampicin being the most investigated antibiotic regimen in HS, the evidence-based literature on their use in HS is limited and primarily based on retrospective studies. [2][3][4][5] Additionally, despite lack of evidence on the long-term risks, the suggested treatment duration is 10 weeks due to the risk of side-effects and concerns regarding antibiotic resistance. 6 Patients with HS who initiated combination therapy with oral clindamycin 300 mg and rifampicin 300 mg twice daily between January 2016 and January 2019 were consecutively enrolled in this open-label, single-group, prospective study conducted at a tertiary referral centre for HS (Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Denmark) with the aim of evaluating the 6-month effectiveness, safety and effect on quality of life.…”